BACKGROUND: Hospices provide end-of-life care for heart failure (HF) patients, but hospice is underused for these patients, and its use has not been well described. METHODS: We examined hospice use among 11,754 HF and 31,228 cancer patients. These patients were either discharged from hospice or died while in hospice between January 1, 2004, and June 30, 2005. RESULTS: The percentages of patients with HF and cancer who received hospice care for </=7 days were similar (31.7% vs 30.8%; P = .08), but HF patients were significantly more likely to receive hospice care for >/=6 months (7.6% vs 1.1%; P < .001). Patients with HF were significantly more likely to be discharged from hospice alive (19.0% vs 11.3%; P < .001), as were African Americans with HF and those who were prescribed HF medications. CONCLUSION: Our study provides detailed estimates of hospice use and identifies potential areas of hospice care that are unique to HF patients. Our findings generate hypotheses about the Medicare Hospice Benefit, specifically whether changes to the 6-month prognosis criterion for hospice eligibility would result in increased hospice use for HF patients. We hope that our results will stimulate additional studies to elucidate differences in hospice use between HF and cancer patients, including patient perspectives of hospice care and clinician referral patterns.
BACKGROUND: Hospices provide end-of-life care for heart failure (HF) patients, but hospice is underused for these patients, and its use has not been well described. METHODS: We examined hospice use among 11,754 HF and 31,228 cancerpatients. These patients were either discharged from hospice or died while in hospice between January 1, 2004, and June 30, 2005. RESULTS: The percentages of patients with HF and cancer who received hospice care for </=7 days were similar (31.7% vs 30.8%; P = .08), but HF patients were significantly more likely to receive hospice care for >/=6 months (7.6% vs 1.1%; P < .001). Patients with HF were significantly more likely to be discharged from hospice alive (19.0% vs 11.3%; P < .001), as were African Americans with HF and those who were prescribed HF medications. CONCLUSION: Our study provides detailed estimates of hospice use and identifies potential areas of hospice care that are unique to HF patients. Our findings generate hypotheses about the Medicare Hospice Benefit, specifically whether changes to the 6-month prognosis criterion for hospice eligibility would result in increased hospice use for HF patients. We hope that our results will stimulate additional studies to elucidate differences in hospice use between HF and cancerpatients, including patient perspectives of hospice care and clinician referral patterns.
Authors: Soko Setoguchi; Robert J Glynn; Margaret Stedman; Carol M Flavell; Raisa Levin; Lynne Warner Stevenson Journal: Am Heart J Date: 2010-07 Impact factor: 4.749
Authors: Laura P Gelfman; Marie Bakitas; Lynne Warner Stevenson; James N Kirkpatrick; Nathan E Goldstein Journal: J Palliat Med Date: 2017-05-12 Impact factor: 2.947
Authors: David A Alter; Dennis T Ko; Jack V Tu; Therese A Stukel; Douglas S Lee; Andreas Laupacis; Alice Chong; Peter C Austin Journal: J Gen Intern Med Date: 2012-05-02 Impact factor: 5.128
Authors: Hillary D Lum; Jacqueline Jones; Dana Lahoff; Larry A Allen; David B Bekelman; Jean S Kutner; Daniel D Matlock Journal: Am Heart J Date: 2015-07-02 Impact factor: 4.749
Authors: Paul A Heidenreich; Nancy M Albert; Larry A Allen; David A Bluemke; Javed Butler; Gregg C Fonarow; John S Ikonomidis; Olga Khavjou; Marvin A Konstam; Thomas M Maddox; Graham Nichol; Michael Pham; Ileana L Piña; Justin G Trogdon Journal: Circ Heart Fail Date: 2013-04-24 Impact factor: 8.790
Authors: Larry A Allen; Lynne W Stevenson; Kathleen L Grady; Nathan E Goldstein; Daniel D Matlock; Robert M Arnold; Nancy R Cook; G Michael Felker; Gary S Francis; Paul J Hauptman; Edward P Havranek; Harlan M Krumholz; Donna Mancini; Barbara Riegel; John A Spertus Journal: Circulation Date: 2012-03-05 Impact factor: 29.690